U.S., March 19 -- ClinicalTrials.gov registry received information related to the study (NCT07480824) titled 'To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects' on March 14.
Brief Summary: This is an open, open-label, parallel, single-dose, phase I clinical study designed to evaluate the pharmacokinetic (PK) profile of TQ05105 tablet in patients with hepatic impairment after a single dose, and to evaluate the safety of the drug in these patients after a single dose.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Myelofibrosis
Intervention:
DRUG: TQ05105
Janus Kinase Inhibitors/Rho-associated Kinase (JAK/ROCK) inhibitors
Recruitment Status: NOT_YET_RECRUITING
Sponsor: ...